-
Patent Agency Ranking
1.发明授权公开(公告)号：US10266897B2
公开(公告)日：2019-04-23
申请号：US15914112
申请日：2018-03-07
Inventor： Rifaat Safadi
IPC: C07H21/02 , C07H21/04 , C12Q1/6883 , A61K31/7088 , A61K45/06 , C12N15/113 , A61K31/713 , A61K31/7105
Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.
-
2.发明授权Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD) 有权NLGn4表达的调节，非酒精性脂肪性肝病（NAFLD）中的NK细胞活性公开(公告)号：US09469855B2
公开(公告)日：2016-10-18
申请号：US14963319
申请日：2015-12-09
Inventor： Rifaat Safadi
IPC: A61K48/00 , C07H21/02 , C07H21/04 , C12N15/113 , A61K31/7088 , A61K45/06 , C12Q1/68 , A61K31/713 , A61K31/7105
CPC classification number: C12Q1/6883 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q2600/158
Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
Abstract translation: 本发明提供通过抑制NGn4表达从而调节NK细胞的活性来治疗，减轻或预防肝脏疾病的方法。 本发明还涉及通过评估NK细胞中的NLGn4表达来诊断肝脏疾病。
-
公开(公告)号：US11718666B2
公开(公告)日：2023-08-08
申请号：US17388218
申请日：2021-07-29
Inventor： Rifaat Safadi
CPC classification number: C07K16/28 , A61K38/16 , A61K38/177 , A61K38/1709 , A61P1/16 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/76 , C07K2319/30
Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
-
公开(公告)号：US11098116B2
公开(公告)日：2021-08-24
申请号：US16407848
申请日：2019-05-09
Inventor： Rifaat Safadi
Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
-
5.发明授权公开(公告)号：US09944988B2
公开(公告)日：2018-04-17
申请号：US15256781
申请日：2016-09-06
Inventor： Rifaat Safadi
IPC: C07H21/02 , C12Q1/68 , A61K31/7088 , A61K45/06 , C12N15/113 , A61K31/713 , A61K31/7105
CPC classification number: C12Q1/6883 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q2600/158
Abstract: The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an NLGn4 gene product in the immune cell population using NLGn4 specific primers or NLGn4 specific probes.
-
-
-
-
Search Results
5
records
(took 0.013 seconds)
